Stampacchia Otello 4
Accession 0001209191-23-054913
Filed
Nov 8, 7:00 PM ET
Accepted
Nov 9, 8:36 PM ET
Size
20.2 KB
Accession
0001209191-23-054913
Insider Transaction Report
- Conversion
Common Stock
2023-11-07+287,213→ 1,703,078 total - Conversion
Series A convertible preferred stock
2023-11-07−14,999,999→ 0 total→ Common Stock (1,415,865 underlying) - Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,157,623 total - Conversion
Series B convertible preferred stock
2023-11-07−2,615,533→ 0 total→ Common Stock (287,213 underlying) - Conversion
Common Stock
2023-11-07+1,415,865→ 1,415,865 total
- Conversion
Common Stock
2023-11-07+1,415,865→ 1,415,865 total - Conversion
Common Stock
2023-11-07+287,213→ 1,703,078 total - Conversion
Series A convertible preferred stock
2023-11-07−14,999,999→ 0 total→ Common Stock (1,415,865 underlying) - Conversion
Series B convertible preferred stock
2023-11-07−2,615,533→ 0 total→ Common Stock (287,213 underlying) - Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,157,623 total
- Conversion
Common Stock
2023-11-07+287,213→ 1,703,078 total - Conversion
Common Stock
2023-11-07+1,415,865→ 1,415,865 total - Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,157,623 total - Conversion
Series A convertible preferred stock
2023-11-07−14,999,999→ 0 total→ Common Stock (1,415,865 underlying) - Conversion
Series B convertible preferred stock
2023-11-07−2,615,533→ 0 total→ Common Stock (287,213 underlying)
- Conversion
Common Stock
2023-11-07+1,415,865→ 1,415,865 total - Conversion
Series A convertible preferred stock
2023-11-07−14,999,999→ 0 total→ Common Stock (1,415,865 underlying) - Conversion
Series B convertible preferred stock
2023-11-07−2,615,533→ 0 total→ Common Stock (287,213 underlying) - Conversion
Common Stock
2023-11-07+287,213→ 1,703,078 total - Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,157,623 total
- Conversion
Common Stock
2023-11-07+1,415,865→ 1,415,865 total - Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,157,623 total - Conversion
Series B convertible preferred stock
2023-11-07−2,615,533→ 0 total→ Common Stock (287,213 underlying) - Conversion
Common Stock
2023-11-07+287,213→ 1,703,078 total - Conversion
Series A convertible preferred stock
2023-11-07−14,999,999→ 0 total→ Common Stock (1,415,865 underlying)
- Conversion
Common Stock
2023-11-07+1,415,865→ 1,415,865 total - Conversion
Series A convertible preferred stock
2023-11-07−14,999,999→ 0 total→ Common Stock (1,415,865 underlying) - Conversion
Series B convertible preferred stock
2023-11-07−2,615,533→ 0 total→ Common Stock (287,213 underlying) - Conversion
Common Stock
2023-11-07+287,213→ 1,703,078 total - Purchase
Common Stock
2023-11-07$11.00/sh+454,545$4,999,995→ 2,157,623 total
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
- [F2]Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
Documents
Issuer
Lexeo Therapeutics, Inc.
CIK 0001907108
Related Parties
1- filerCIK 0001361712
Filing Metadata
- Form type
- 4
- Filed
- Nov 8, 7:00 PM ET
- Accepted
- Nov 9, 8:36 PM ET
- Size
- 20.2 KB